Cargando…
Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202577/ https://www.ncbi.nlm.nih.gov/pubmed/35719141 http://dx.doi.org/10.3389/fnut.2022.890357 |
_version_ | 1784728558462042112 |
---|---|
author | Zhao, Hui-jun Zhang, Xiao-jing Zhang, Na-na Yan, Bin Xu, Ke-ke Peng, Li-hua Pan, Fei |
author_facet | Zhao, Hui-jun Zhang, Xiao-jing Zhang, Na-na Yan, Bin Xu, Ke-ke Peng, Li-hua Pan, Fei |
author_sort | Zhao, Hui-jun |
collection | PubMed |
description | BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for the treatment of IBS patients with subgroup analyses to explore the most effective way of FMT for IBS. METHODS: All eligible studies were searched from PubMed, Embase, Web of Science, and the Cochrane Library through multiple search strategies. Data were extracted from studies comprising the following criteria: double-blind, randomized controlled trials (RCTs) that compared the efficacy of FMT with placebo for adult patients (≥18 years old) with IBS. A meta-analysis was performed to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs). RESULTS: A total of seven RCTs comprising 489 subjects were eligible for this meta-analysis. Pooled data showed no significant improvement of global IBS symptoms in patients with FMT compared with placebo (RR = 1.34; 95% CI 0.75–2.41, p = 0.32). A significant heterogeneity was observed among the studies (I(2) = 83%, p < 0.00001). There was no significant evidence of funnel plot asymmetry (Egger's test, p = 0.719; Begg's test, p = 1.000), indicating no existence of publication bias. Subgroup analyses revealed that FMT operated by invasive routes, including gastroscope, colonoscope, and nasojejunal tube, significantly improved global IBS symptoms (RR = 1.96; 95% CI 1.23–3.11, p = 0.004) with heterogeneity (I(2) = 57%, p = 0.06) and an NNT of 3 (95% CI 2–14). However, FMT delivered via oral capsules showed a negative impact on patients with IBS (RR = 0.56; 95% CI 0.33–0.96, p = 0.03) with a low heterogeneity (I(2) = 39%, p = 0.2) and an NNH of 3 (95% CI 2–37). CONCLUSION: The current evidence from RCTs with all routes of FMT does not show significant global improvement in patients with IBS. However, FMT operated by invasive routes significantly improved global IBS symptoms. |
format | Online Article Text |
id | pubmed-9202577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92025772022-06-17 Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials Zhao, Hui-jun Zhang, Xiao-jing Zhang, Na-na Yan, Bin Xu, Ke-ke Peng, Li-hua Pan, Fei Front Nutr Nutrition BACKGROUND: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients. OBJECTIVE: To conduct a meta-analysis and estimate the efficacy and safety of FMT for the treatment of IBS patients with subgroup analyses to explore the most effective way of FMT for IBS. METHODS: All eligible studies were searched from PubMed, Embase, Web of Science, and the Cochrane Library through multiple search strategies. Data were extracted from studies comprising the following criteria: double-blind, randomized controlled trials (RCTs) that compared the efficacy of FMT with placebo for adult patients (≥18 years old) with IBS. A meta-analysis was performed to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs). RESULTS: A total of seven RCTs comprising 489 subjects were eligible for this meta-analysis. Pooled data showed no significant improvement of global IBS symptoms in patients with FMT compared with placebo (RR = 1.34; 95% CI 0.75–2.41, p = 0.32). A significant heterogeneity was observed among the studies (I(2) = 83%, p < 0.00001). There was no significant evidence of funnel plot asymmetry (Egger's test, p = 0.719; Begg's test, p = 1.000), indicating no existence of publication bias. Subgroup analyses revealed that FMT operated by invasive routes, including gastroscope, colonoscope, and nasojejunal tube, significantly improved global IBS symptoms (RR = 1.96; 95% CI 1.23–3.11, p = 0.004) with heterogeneity (I(2) = 57%, p = 0.06) and an NNT of 3 (95% CI 2–14). However, FMT delivered via oral capsules showed a negative impact on patients with IBS (RR = 0.56; 95% CI 0.33–0.96, p = 0.03) with a low heterogeneity (I(2) = 39%, p = 0.2) and an NNH of 3 (95% CI 2–37). CONCLUSION: The current evidence from RCTs with all routes of FMT does not show significant global improvement in patients with IBS. However, FMT operated by invasive routes significantly improved global IBS symptoms. Frontiers Media S.A. 2022-05-27 /pmc/articles/PMC9202577/ /pubmed/35719141 http://dx.doi.org/10.3389/fnut.2022.890357 Text en Copyright © 2022 Zhao, Zhang, Zhang, Yan, Xu, Peng and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Zhao, Hui-jun Zhang, Xiao-jing Zhang, Na-na Yan, Bin Xu, Ke-ke Peng, Li-hua Pan, Fei Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title | Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_full | Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_fullStr | Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_short | Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials |
title_sort | fecal microbiota transplantation for patients with irritable bowel syndrome: a meta-analysis of randomized controlled trials |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202577/ https://www.ncbi.nlm.nih.gov/pubmed/35719141 http://dx.doi.org/10.3389/fnut.2022.890357 |
work_keys_str_mv | AT zhaohuijun fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT zhangxiaojing fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT zhangnana fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT yanbin fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT xukeke fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT penglihua fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials AT panfei fecalmicrobiotatransplantationforpatientswithirritablebowelsyndromeametaanalysisofrandomizedcontrolledtrials |